Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

48 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effects of the acyl coenzyme A:cholesterol acyltransferase inhibitor avasimibe on human atherosclerotic lesions.
Tardif JC, Grégoire J, L'Allier PL, Anderson TJ, Bertrand O, Reeves F, Title LM, Alfonso F, Schampaert E, Hassan A, McLain R, Pressler ML, Ibrahim R, Lespérance J, Blue J, Heinonen T, Rodés-Cabau J; Avasimibe and Progression of Lesions on UltraSound (A-PLUS) Investigators. Tardif JC, et al. Among authors: title lm. Circulation. 2004 Nov 23;110(21):3372-7. doi: 10.1161/01.CIR.0000147777.12010.EF. Epub 2004 Nov 8. Circulation. 2004. PMID: 15533865 Clinical Trial.
Effects of AGI-1067 and probucol after percutaneous coronary interventions.
Tardif JC, Grégoire J, Schwartz L, Title L, Laramée L, Reeves F, Lespérance J, Bourassa MG, L'Allier PL, Glass M, Lambert J, Guertin MC; Canadian Antioxidant Restenosis Trial (CART-1) Investigators. Tardif JC, et al. Circulation. 2003 Feb 4;107(4):552-8. doi: 10.1161/01.cir.0000047525.58618.3c. Circulation. 2003. PMID: 12566365 Clinical Trial.
Effects of the antioxidant succinobucol (AGI-1067) on human atherosclerosis in a randomized clinical trial.
Tardif JC, Grégoire J, L'Allier PL, Ibrahim R, Anderson TJ, Reeves F, Title LM, Schampaert E, LeMay M, Lespérance J, Scott R, Guertin MC, Brennan ML, Hazen SL, Bertrand OF; CART-2 Investigators. Tardif JC, et al. Among authors: title lm. Atherosclerosis. 2008 Mar;197(1):480-6. doi: 10.1016/j.atherosclerosis.2006.11.039. Epub 2007 Jan 9. Atherosclerosis. 2008. PMID: 17214993 Clinical Trial.
The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS).
Schampaert E, Cohen EA, Schlüter M, Reeves F, Traboulsi M, Title LM, Kuntz RE, Popma JJ; C-SIRIUS Investigators. Schampaert E, et al. Among authors: title lm. J Am Coll Cardiol. 2004 Mar 17;43(6):1110-5. doi: 10.1016/j.jacc.2004.01.024. J Am Coll Cardiol. 2004. PMID: 15028375 Free article. Clinical Trial.
Cardiometabolic effects of rosiglitazone in patients with type 2 diabetes and coronary artery bypass grafts: A randomized placebo-controlled clinical trial.
Bertrand OF, Poirier P, Rodés-Cabau J, Rinfret S, Title LM, Dzavik V, Natarajan M, Angel J, Batalla N, Alméras N, Costerousse O, De Larochellière R, Roy L, Després JP; VICTORY Trial Investigators. Bertrand OF, et al. Among authors: title lm. Atherosclerosis. 2010 Aug;211(2):565-73. doi: 10.1016/j.atherosclerosis.2010.06.005. Epub 2010 Jun 11. Atherosclerosis. 2010. PMID: 20594555 Clinical Trial.
A multicentre, randomized, double-blind placebo-controlled trial evaluating rosiglitazone for the prevention of atherosclerosis progression after coronary artery bypass graft surgery in patients with type 2 diabetes. Design and rationale of the VeIn-Coronary aTherOsclerosis and Rosiglitazone after bypass surgerY (VICTORY) trial.
Bertrand OF, Poirier P, Rodés-Cabau J, Rinfret S, Title L, Dzavik V, Natarajan M, Angel J, Batalla N, Alméras N, Costerousse O, De Larochellière R, Roy L, Després JP; VICTORY trial investigators. Bertrand OF, et al. Can J Cardiol. 2009 Sep;25(9):509-15. doi: 10.1016/s0828-282x(09)70136-9. Can J Cardiol. 2009. PMID: 19746240 Free PMC article. Clinical Trial.
48 results